Find trials
Search tips

A Study of Course and Treatment Outcomes of Paraneoplastic Neurological Disorders and Other CNS Inflammatory Disorders

Overview

About this study

The purpose of this study is to evaluate Mayo patients who have been seropositive for paraneoplastic antibodies with regards to their treatments and symptom progress.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

GROUP 1 

  • Patients with neurological diseases who are positive for paraneoplastic antibodies with or without cancer identified in the Mayo Neuroimmunology Laboratory. 

Exclusion Criteria: 

  • Patients without paraneoplatic antibodies or with clear alternative explanation for their symptoms.

GROUP 2

Inclusion Criteria:

  • Patients with inflammatory neurological diseases who have had biopsies done.  

Exclusion Criteria:

  • Patients that do not have inflammatory CNS disorders and have not had a biopsy completed or reviewed at Mayo Clinic.

 

 

 

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Sean Pittock, M.D.

Closed-enrolling by invitation

What is this? (?)
"Close"
Not open to everyone who meets the eligibility criteria, but only those invited to participate by the study team.

Contact information:

Jessica Sagen M.A.

(507) 538-3761

Sagen.Jessica@mayo.edu

More information

Publications

Publications are currently not available

More about research at Mayo Clinic

.
CLS-20316350

Mayo Clinic Footer